Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 May 3

PMID 33936066

Citations 20

Authors

Hui Lu

Peng-Fei Wu

Wan Zhang

Xiaoyao Liao

Affiliations

Soon will be listed here.

Abstract

Background: Previous research have implicated critical roles of systemic inflammation in the development of Multiple Sclerosis (MS). But the causal relationship between interleukins (ILs) and MS has not been fully elucidated.

Objective: In this study, we applied Mendelian randomization (MR) approaches to address the causal associations between genetically determined circulating levels of ILs and the risk of MS.

Methods: Genetic instruments for circulating IL-1 receptor antagonist (IL-1Ra), IL-2 receptor α subunit (IL-2Rα), IL-6, IL-16, IL-17, and IL-18 were obtained from recently published genome-wide association studies (GWAS). Summary-level data for MS were obtained from the International Multiple Sclerosis Genetics Consortium. MR analyses were performed using the R software (version 3.6.1, The R Foundation) and the TwoSampleMR package.

Results: Genetic predisposition to higher circulating levels of IL-2Rα were significantly associated with MS risk. The odds ratio (OR) was 1.22 (95% confidence interval [CI], 1.12-1.32; < 0.001) per one standard deviation increase in circulating IL-2Rα levels. There was a suggestive association of circulating IL-1Ra with MS risk (OR, 0.94; 95% CI, 0.88-0.99; = 0.027). The other ILs were not associated with the outcome.

Conclusion: Our results indicated that circulating IL-2Rα was causally associated with risk of MS.

Citing Articles

The association between benign and malignant prostatic hyperplastic diseases and blood and urine biomarkers: A Mendelian randomization study.

Lin Z, Zhang Z, Ning G, Huang S, Yang D, Wu B Medicine (Baltimore). 2025; 104(10):e41723.

PMID: 40068042 PMC: 11903025. DOI: 10.1097/MD.0000000000041723.

Genes, Gene Loci, and Their Impacts on the Immune System in the Development of Multiple Sclerosis: A Systematic Review.

Arneth B Int J Mol Sci. 2024; 25(23).

PMID: 39684620 PMC: 11641802. DOI: 10.3390/ijms252312906.

Study on the anti-atherosclerosis mechanisms of Tanyu Tongzhi formula based on network pharmacology, Mendelian randomization, and experimental verification.

Dai J, Zhou X, Xu X, Qiu Y, Chen S, Mao W Pharm Biol. 2024; 62(1):790-802.

PMID: 39450854 PMC: 11514399. DOI: 10.1080/13880209.2024.2415666.

Can Selected Parameters of Brain Injury Reflect Neuronal Damage in Smoldering Multiple Sclerosis?.

Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiolek M, Zalejska-Fiolka J, Czuba Z Diagnostics (Basel). 2024; 14(17).

PMID: 39272777 PMC: 11394557. DOI: 10.3390/diagnostics14171993.

Mendelian Randomization Analysis of Circulating Cytokines and Risk of Autoimmune Neuroinflammatory Diseases.

Tao S, Cao F, Zhang R, Xu S, Li X, Tang J Immunotargets Ther. 2024; 13:273-286.

PMID: 38881648 PMC: 11178096. DOI: 10.2147/ITT.S456326.

References

Kim H, Imbert J, Leonard W . Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006; 17(5):349-66. DOI: 10.1016/j.cytogfr.2006.07.003. View

Zhang H, Wang T, Han Z, Liu G . Mendelian randomization study to evaluate the effects of interleukin-6 signaling on four neurodegenerative diseases. Neurol Sci. 2020; 41(10):2875-2882. DOI: 10.1007/s10072-020-04381-x. View

McGinley A, Edwards S, Raverdeau M, Mills K . Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. J Autoimmun. 2018; . DOI: 10.1016/j.jaut.2018.01.001. View

Davey Smith G, Ebrahim S . 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32(1):1-22. DOI: 10.1093/ije/dyg070. View

Rossi S, Motta C, Studer V, Macchiarulo G, Volpe E, Barbieri F . Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener. 2014; 9:56. PMC: 4292815. DOI: 10.1186/1750-1326-9-56. View

Tsukada N, Matsuda M, Miyagi K, Yanagisawa N . Soluble CD4 and CD8 in the peripheral blood of patients with multiple sclerosis and HTLV-1-associated myelopathy. J Neuroimmunol. 1991; 35(1-3):285-93. DOI: 10.1016/0165-5728(91)90182-7. View

Maier L, Anderson D, Severson C, Baecher-Allan C, Healy B, Liu D . Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol. 2009; 182(3):1541-7. PMC: 3992946. DOI: 10.4049/jimmunol.182.3.1541. View

Ahola-Olli A, Wurtz P, Havulinna A, Aalto K, Pitkanen N, Lehtimaki T . Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2016; 100(1):40-50. PMC: 5223028. DOI: 10.1016/j.ajhg.2016.11.007. View

Herder C, Nuotio M, Shah S, Blankenberg S, Brunner E, Carstensen M . Genetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits. Diabetes. 2014; 63(12):4343-59. PMC: 4237993. DOI: 10.2337/db14-0731. View

10.

Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F . Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012; 71(1):76-83. DOI: 10.1002/ana.22512. View

11.

. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16(11):877-897. PMC: 5641502. DOI: 10.1016/S1474-4422(17)30299-5. View

12.

Rose J, Giovannoni G, Wiendl H, Gold R, Havrdova E, Kappos L . Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017; 17:32-40. DOI: 10.1016/j.msard.2017.06.006. View

13.

Hewett S, Jackman N, Claycomb R . Interleukin-1β in Central Nervous System Injury and Repair. Eur J Neurodegener Dis. 2015; 1(2):195-211. PMC: 4465544. View

14.

Reich D, Lucchinetti C, Calabresi P . Multiple Sclerosis. N Engl J Med. 2018; 378(2):169-180. PMC: 6942519. DOI: 10.1056/NEJMra1401483. View

15.

Boyman O, Sprent J . The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012; 12(3):180-90. DOI: 10.1038/nri3156. View

16.

Brosnan C, Cannella B, Battistini L, Raine C . Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 1995; 45(6 Suppl 6):S16-21. DOI: 10.1212/wnl.45.6_suppl_6.s16. View

17.

Naitza S, Porcu E, Steri M, Taub D, Mulas A, Xiao X . A genome-wide association scan on the levels of markers of inflammation in Sardinians reveals associations that underpin its complex regulation. PLoS Genet. 2012; 8(1):e1002480. PMC: 3266885. DOI: 10.1371/journal.pgen.1002480. View

18.

Dinarello C . Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009; 27:519-50. DOI: 10.1146/annurev.immunol.021908.132612. View

19.

Al-Nashmi M, Taha S, Alsharoqi I, Bakhiet M . Interleukin 1 receptor antagonist and 2'-5'-oligoadenylate synthetase-like molecules as novel biomarkers for multiple sclerosis patients in Bahrain. Mult Scler Relat Disord. 2017; 18:1-7. DOI: 10.1016/j.msard.2017.09.001. View

20.

Govindarajan V, de Rivero Vaccari J, Keane R . Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J Neuroinflammation. 2020; 17(1):260. PMC: 7469327. DOI: 10.1186/s12974-020-01944-9. View